Genetron Holdings Limited ("Genetron Health" or the "Company") is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products.
Company profile
Ticker
GTH
Exchange
Website
CEO
Si Zhen Wang
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
GTH stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
18 Jan 23
UPLOAD
Letter from SEC
8 Nov 22
6-K
Current report (foreign)
3 Nov 22
CORRESP
Correspondence with SEC
3 Nov 22
UPLOAD
Letter from SEC
27 Oct 22
6-K
Genetron Health Reports Unaudited Second Quarter 2022 Financial Results
12 Oct 22
CORRESP
Correspondence with SEC
30 Sep 22
6-K
Genetron Health Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee
2 Sep 22
6-K
Genetron Health Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company
22 Aug 22
UPLOAD
Letter from SEC
16 Aug 22
Latest ownership filings
SC 13G
Tianjin Kangyue Business Management Partnership (Limited Partnership)
14 Mar 22
SC 13G/A
Wang Sizhen
14 Feb 22
SC 13G/A
Tianjin Genetron Jun'an Business Management Partnership (Limited Partnership)
14 Feb 22
SC 13G/A
Yan Hai
14 Feb 22
SC 13G/A
BlackRock Inc.
10 Sep 21
SC 13G
Wealth Strategy Group Ltd
28 Apr 21
SC 13G
Tianjin Genetron Jun'an Business Management Partnership (Limited Partnership)
12 Feb 21
SC 13G
Wang Sizhen
12 Feb 21
SC 13G
Yan Hai
12 Feb 21
SC 13G
BlackRock Inc.
2 Feb 21
Financial summary
| Quarter (USD) | Dec 21 | Dec 20 | |
|---|---|---|---|
| Revenue | |||
| Cost of revenue | |||
| Operating income | |||
| Operating margin | |||
| Net income | |||
| Net profit margin | |||
| Cash on hand | |||
| Change in cash | |||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | |
|---|---|---|---|
| Revenue | |||
| Cost of revenue | |||
| Operating income | |||
| Operating margin | |||
| Net income | |||
| Net profit margin | |||
| Cash on hand | |||
| Change in cash | |||
| Diluted EPS |
Institutional ownership, Q3 2022
| 13F holders | Current |
|---|---|
| Total holders | 27 |
| Opened positions | 4 |
| Closed positions | 15 |
| Increased positions | 2 |
| Reduced positions | 9 |
| 13F shares | Current |
|---|---|
| Total value | 1.26 bn |
| Total shares | 223.85 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Wang Sizhen | 75.47 mm | $0.00 |
| Tianjin Kangyue Business Management Partnership | 57.82 mm | $352.73 mm |
| Vivo Capital IX | 28.57 mm | $410.33 mm |
| Tianjin Genetron Jun'an Business Management Partnership | 26.08 mm | $159.11 mm |
| Wealth Strategy | 23.40 mm | $327.62 mm |
| Vivo Capital | 8.12 mm | $6.35 mm |
| Hudson Bay Capital Management | 933.87 k | $730.00 k |
| Platinum Investment Management | 746.86 k | $584.00 k |
| Vanguard | 735.25 k | $575.00 k |
| BLK Blackrock | 507.72 k | $397.00 k |